4.4 Article

Mechanisms of thrombosis in systemic lupus erythematosus and antiphospholipid syndrome

Journal

BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
Volume 31, Issue 3, Pages 334-341

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.berh.2017.09.008

Keywords

beta(2)-glycoprotein I; Antiphospholipid; Cell activation; Lupus anticoagulant; Complement; Mouse models; Prothrombin; Anionic phospholipids

Categories

Ask authors/readers for more resources

The presence of antiphospholipid antibodies is one of the most common acquired risk factors for thrombosis. Antiphospholipid antibodies is a collective term for a set of autoantibodies with closely related but different specificity. Experiments in which isolated patient antibodies were injected into mice have shown that a specific subset of autoantibodies, those directed against the first domain of plasma protein beta(2)-glycoprotein I, can explain the increased risk of thrombosis. Experiments performed with these mice have shown that autoantibodies against beta(2)-glycoprotein I bind to and activate cells such as endothelial cells, monocytes, and platelets. Activation of these cells, all involved in the regulation of hemostasis, results in a shift towards a prothrombotic state. How this process is regulated, whether this is the only mechanism involved, and whether this is the only subpopulation responsible for the increased thrombotic risk is unknown. In this review, we will critically discuss what is known and what is debatable on the pathophysiology of antiphospholipid syndrome. (C) 2017 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available